Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Autolus Therapeutics plc (AUTL)
Newly released Crypto mining rig for Autolus Therapeutics plc coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK
6 days ago | Benzinga
Here's Why Autolus Therapeutics Is Surging Today
a week ago | The Motley Fool
AUTL Stock Increases Over 15% Pre-Market: Why It Happened
a week ago | Pulse2
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
a month ago | GlobeNewsWire
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
a month ago | GlobeNewsWire
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
2 months ago | GlobeNewsWire
Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort
2 months ago | Benzinga
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
2 months ago | GlobeNewsWire
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
2 months ago | GlobeNewsWire
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021
2 months ago | GlobeNewsWire

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

376

Address:

Autolus Therapeutics plc Forest House 58 Wood Lane White City London W12 7RZ United Kingdom

Website:

http://www.autolus.com

Phone:

44 20 3829 6230

Leave a comment

Your email address will not be published. Required fields are marked *